Postpartum Support International Statement on FDA Approval of the First Treatment for Postpartum Depression

PORTLAND, Ore, March 25, 2019 / PRNewswire / – On March 19thBrexanolone, the first treatment specifically indicated for postpartum depression, has been approved by the US Food and Drug Administration (FDA).

"As the leading organization defending the interests of women and families, Postpartum Support International (PSI) supports the FDA's decision to approve this new treatment that can benefit women with postpartum depression," he said. Ann Smith, CNM, president of PSI.

The new treatment will require a hospital infusion and is expected to be available in the summer of 2019.

"It's important to recognize that treatment options for postpartum depression include self-help strategies, support groups and counseling, in addition to medications, and we want families to know that currently available medications are effective. for many, but that there is a treatment specifically designed for PPD and whose effectiveness and demonstrated improvements are an important step, "he said. Wendy Davis, PhD, Executive Director of PSI.

"We recognize that a holistic approach is essential to recovery. That's why we provide volunteers and support groups in the 50 states and in 49 countries. We also educate families, train providers and advocate for awareness and better access to perinatal mental health care. Women need to know that they are not alone, that they are not to blame and that they will recover with a personal care plan, informed treatment and support, "she continued.

Not less than one in seven new mothers suffers from depression or postpartum anxiety. According to one 2016 study published in the Journal of Perinatal Psychiatry, less than 40% of women with PPD are actually diagnosed and less than 10% receive adequate treatment. The majority of women do not ask for help for various reasons, including lack of access, shame and stigma, and because they do not understand the symptoms of depression. This isolation leaves them alone suffering from symptoms ranging from sadness to anxiety through intrusive fears, insomnia, anger and despair.

"Women and families do not need to suffer from this devastating disease that affects children, partners, families and communities, and women should have access to screening, life-saving treatment, support and services, training, and referrals to local specialists We know that women can improve and we are here to help them find what they need to recover, "he said. Ann Smith, CNM, president of PSI.

If you or any of your acquaintances need help, call the PSI Helpline at 800.944.4PPD, call 503-894-9453 or visit the PSI website at www.postpartum.net

Media contact:
Jessica Peterson
[email protected]
360-608-7935

SOURCE Postpartum Support International

Related Links

https://www.postpartum.net